Skip to main content

Table 1 Distribution of patient and tumor characteristics by body mass index (BMI) group

From: The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial

   Total (n = 3754) BMI (kg/m2) p valuea
   <25.0 25.0–29.9 30.0–34.9 35.0–39.9 ≥40.0
   Underweight/normal weight Overweight Slightly obese Moderately obese Severely obese
   (n = 1758) (n = 1208) (n = 554) (n = 177) (n = 57)
Age (years) Median 53.0 50.0 56.0 58.0 58.0 54.0 <0.001b
Range 21–86 21–86 22–79 32–77 33–74 29–74
Menopausal status Premenopausal 1565 (41.7 %) 932 (53.0 %) 410 (33.9 %) 153 (27.6 %) 52 (29.4 %) 18 (31.6 %) <0.001c
Postmenopausal 2189 (58.3 %) 826 (47.0 %) 798 (66.1 %) 401 (72.4 %) 125 (70.6 %) 39 (68.4 %)
Tumor size pT1 1552 (41.3 %) 866 (49.3 %) 455 (37.7 %) 161 (29.1 %) 56 (31.6 %) 14 (24.6 %) <0.001d
pT2 1929 (51.4 %) 785 (44.7 %) 666 (55.1 %) 342 (61.7 %) 101 (57.1 %) 35 (61.4 %)
pT3 198 (5.3 %) 73 (4.2 %) 70 (5.8 %) 35 (6.3 %) 14 (7.9 %) 6 (10.5 %)
pT4 52 (1.4 %) 18 (1.0 %) 13 (1.1 %) 13 (2.3 %) 6 (3.4 %) 2 (3.5 %)
Unknown 23 (0.6 %) 16 (0.9 %) 4 (0.3 %) 3 (0.5 %) 0 (0.0 %) 0 (0.0 %)
Nodal stage pN0 1273 (33.9 %) 660 (37.5 %) 370 (30.6 %) 153 (27.6 %) 67 (37.9 %) 23 (40.4 %) <0.001d
pN1 1705 (45.4 %) 789 (44.9 %) 564 (46.7 %) 265 (47.8 %) 68 (38.4 %) 19 (33.3 %)
pN2 511 (13.6 %) 212 (12.1 %) 174 (14.4 %) 94 (17.0 %) 24 (13.6 %) 7 (12.3 %)
pN3 236 (6.3 %) 76 (4.3 %) 94 (7.8 %) 40 (7.2 %) 18 (10.2 %) 8 (14.0 %)
Unknown 29 (0.8 %) 21 (1.2 %) 6 (0.5 %) 2 (0.4 %) 0 (0.0 %) 0 (0.0 %)
Histological grading G1 176 (4.7 %) 81 (4.6 %) 59 (4.9 %) 27 (4.9 %) 8 (4.5 %) 1 (1.8 %) 0.126d
G2 1783 (47.5 %) 848 (48.2 %) 576 (47.7 %) 255 (46.0 %) 82 (46.3 %) 22 (38.6 %)
G3 1773 (47.2 %) 814 (46.3 %) 568 (47.0 %) 270 (48.7 %) 87 (49.2 %) 34 (59.6 %)
Unknown 22 (0.6 %) 15 (0.9 %) 5 (0.4 %) 2 (0.4 %) 0 (0.0 %) 0 (0.0 %)
Histological type Invasive ductal 3060 (81.5 %) 1434 (81.6 %) 992 (82.1 %) 435 (78.5 %) 148 (83.6 %) 51 (89.5 %) 0.337c
Invasive lobular 419 (11.2 %) 188 (10.7 %) 138 (11.4 %) 72 (13.0 %) 19 (10.7 %) 2 (3.5 %)
Other 253 (6.7 %) 121 (6.9 %) 73 (6.0 %) 45 (8.1 %) 10 (5.6 %) 4 (7.0 %)
Unknown 22 (0.6 %) 15 (0.9 %) 5 (0.4 %) 2 (0.4 %) 0 (0.0 %) 0 (0.0 %)
Hormone receptor status Negative 1100 (29.3 %) 531 (30.2 %) 337 (27.9 %) 163 (29.4 %) 44 (24.9 %) 25 (43.9 %) 0.049c
Positive 2633 (70.1 %) 1212 (68.9 %) 866 (71.7 %) 390 (70.4 %) 133 (75.1 %) 32 (56.1 %)
Unknown 21 (0.6 %) 15 (0.9 %) 5 (0.4 %) 1 (0.2 %) 0 (0.0 %) 0 (0.0 %)
HER2 status Negative 2787 (74.2 %) 1304 (74.2 %) 887 (73.4 %) 417 (75.3 %) 135 (76.3 %) 44 (77.2 %) 0.838c
Positive 883 (23.5 %) 418 (23.8 %) 292 (24.2 %) 122 (22.0 %) 39 (22.0 %) 12 (21.1 %)
Unknown 84 (2.2 %) 36 (2.0 %) 29 (2.4 %) 15 (2.7 %) 3 (1.7 %) 1 (1.8 %)
Molecular subtype Luminal A like 1426 (38.0 %) 673 (38.3 %) 454 (37.6 %) 222 (40.1 %) 63 (35.6 %) 14 (24.6 %) 0.050c
Luminal B like 619 (16.5 %) 262 (14.9 %) 214 (17.7 %) 93 (16.8 %) 39 (22.0 %) 11 (19.3 %)
HER2 positive 883 (23.5 %) 418 (23.8 %) 292 (24.2 %) 122 (22.0 %) 39 (22.0 %) 12 (21.1 %)
Triple negative 742 (19.8 %) 369 (21.0 %) 219 (18.1 %) 102 (18.4 %) 33 (18.6 %) 19 (33.3 %)
Unknown 84 (2.2 %) 36 (2.0 %) 29 (2.4 %) 15 (2.7 %) 3 (1.7 %) 1 (1.8 %)
Type of surgery Breast conserving 2638 (70.3 %) 1205 (68.5 %) 859 (71.1 %) 399 (72.0 %) 135 (76.3 %) 40 (70.2 %) 0.229c
Mastectomy 1097 (29.2 %) 539 (30.7 %) 345 (28.6 %) 154 (27.8 %) 42 (23.7 %) 17 (29.8 %)
Unknown 19 (0.5 %) 14 (0.8 %) 4 (0.3 %) 1 (0.2 %) 0 (0.0 %) 0 (0.0 %)
Chemotherapy FEC-DocG 1856 (49.4 %) 865 (49.2 %) 614 (50.8 %) 261 (47.1 %) 85 (48.0 %) 31 (54.4 %) 0.580c
FEC-Doc 1898 (50.6 %) 893 (50.8 %) 594 (49.2 %) 293 (52.9 %) 92 (52.0 %) 26 (45.6 %)
Undertreatment Yes (<6 cycles CT) 359 (9.6 %) 149 (8.5 %) 113 (9.4 %) 64 (11.6 %) 24 (13.6 %) 9 (15.8 %) 0.029c
No (6 cycles CT) 3395 (90.4 %) 1609 (91.5 %) 1095 (90.6 %) 490 (88.4 %) 153 (86.4 %) 48 (84.2 %)
Antihormone therapy No 1048 (27.9 %) 500 (28.4 %) 331 (27.4 %) 149 (26.9 %) 43 (24.3 %) 25 (43.9 %) 0.061c
Yes 2677 (71.3 %) 1242 (70.6 %) 868 (71.9 %) 401 (72.4 %) 134 (75.7 %) 32 (56.1 %)
Unknown 29 (0.8 %) 16 (0.9 %) 9 (0.7 %) 4 (0.7 %) 0 (0.0 %) 0 (0.0 %)
  1. HER2 human epidermal growth factor receptor 2, FEC-DocG 5-fluorouracile, epirubicine, cyclophosphamide – docetaxel, gemcitabine, FEC-Doc 5-fluorouracile, epirubicine, cyclophosphamide – docetaxel, CT chemotherapy
  2. aAll tests without category “unknown”
  3. bKruskal-Wallis test
  4. cChi-square test
  5. dMantel-Haenszel linear-by-linear association chi-square test